Preferred Label : cancer, second primary;

UMLS semantic type : T191 - Neoplastic Process;

Details


Main resources

You can consult :


https://ansm.sante.fr/informations-de-securite/xgeva-denosumab-v-risque-de-second-cancer-primitif
2018
false
false
false
France
French
pharmacovigilance note
Denosumab
denosumab
injections, subcutaneous
neoplasms, second primary
Advanced Malignant Neoplasm
risk assessment
bone neoplasms
giant cell tumor of bone
product surveillance, postmarketing
cancer, second primary

---
https://www.e-cancer.fr/Professionnels-de-sante/Facteurs-de-risque-et-de-protection/Second-cancer-primitif
2013
France
scientific and technical information
risk factor for malignancy
risk factors
cancer, second primary
Second cancer
Protective Factors
neoplasms, second primary
neoplasm, malignant
risk factor

---
Nous contacter.
28/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.